News Search Results
Dec 16, 2025, 13:53 ET The Surgery Center of Rhode Island Recognized as Leapfrog Top Ambulatory Surgery Center for Third Consecutive Year
Island, SCRI opened in 2008 through a partnership with Constitution Surgery Alliance (CSA) and 35 surgeons specializing in ear, nose, throat, and ophthalmology procedures. Since then, SCRI has built a reputation for world-class outpatient surgical care in a state-of-the-art environment."Receiving
More news about: Constitution Surgery Alliance
Dec 16, 2025, 08:30 ET East Bay Surgery Center Named a Leapfrog "Top Ambulatory Surgery Center" for 2025
patient satisfaction metrics.Notably, EBSC was also named among U.S. News & World Report's "Best Ambulatory Surgery Centers" for ophthalmology in both 2024 and 2025, further cementing its reputation as a regional and national leader in outpatient surgical care.EBSC opened in 2005
More news about: Constitution Surgery Alliance
Dec 16, 2025, 08:30 ET 5 Hartford HealthCare ambulatory surgery centers recognized nationally with Leapfrog award
ASCs are part of a network providing access to outpatient surgical care in orthopedics, total joint replacement, spine surgery pain management and ophthalmology. CSA, a leading developer and operator of outpatient surgery centers, is the managing partner of the ASCs."Achievements like this inspire
More news about: Constitution Surgery Alliance
Dec 16, 2025, 06:03 ET HelpMeSee Welcomes Renowned Ophthalmologist Dr. Jack Cioffi to Its Board of Directors
Chair of the Department of Ophthalmology at Columbia University Irving Medical Center, and Ophthalmologist-in-Chief at New York-Presbyterian Hospital/Columbia. He previously held leadership roles as Director of the Devers Eye Institute and Chair of the Department of Ophthalmology & Chief Medical Officer
More news about: HelpMeSee
Dec 15, 2025, 09:10 ET The Leapfrog Group Announces 2025 Top Hospitals and Top ASCs
2025 Top ASC Award. ASCs in nine surgical specialties are represented:gastroenterology,general surgery,ophthalmology,otolaryngology,orthopedic surgery,urology,neurological surgery,obstetrics and gynecology, andplastic
More news about: The Leapfrog Group
Dec 15, 2025, 09:00 ET Switchboard, MD Surpasses 800,000 Communications Triaged as it Expands Toward End-to-End Clinical Workflow Automation
Over the past year, Switchboard, MD saw a 10x increase in triaged communications as adoption expanded across primary care, orthopedics, and ophthalmology. Health organizations are increasingly adopting Switchboard's multimodal AI infrastructure to reduce administrative burden, simplify front-line
More news about: Switchboard, MD
Dec 15, 2025, 01:00 ET Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
associate companies, AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Dec 15, 2025, 00:49 ET Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
associate companies, AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Dec 11, 2025, 09:06 ET ZEISS celebrates 100 years of advancing innovation in the U.S.
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: ZEISS Group
Dec 10, 2025, 18:30 ET Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Dec 10, 2025, 14:47 ET Inner Circle acknowledges Rahil A. Bandukwala, D.O., as a Pinnacle Professional Member Inner Circle of Excellence
Medicine. He is board certified in internal medicine and board eligible in endocrinology.Affiliated with the American Osteopathic Colleges of Ophthalmology and Otolaryngology and Americans for Free Choice in Medicine, Dr. Bandukwala remains actively engaged in his field while continuously advancing
More news about: The Inner Circle
Dec 10, 2025, 04:00 ET NTC, BACKED BY WISE EQUITY, COMPLETES THE ACQUISITION OF PHARMATHEN'S OPHTHALMOLOGY BUSINESS
NTC S.r.l., one of the leading Italian pharmaceutical companies focused on ophthalmology, along with its main shareholder Wise Equity, announce the completion of the acquisition of Pharmathen's ophthalmology business. The acquisition adds to NTC a consolidated and global portfolio of
More news about: NTC Srl
Dec 10, 2025, 04:00 ET NTC, SOUTENU PAR WISE EQUITY, FINALISE L'ACQUISITION DE L'ACTIVITE OPHTALMOLOGIQUE DE PHARMATHEN
spécialisées dans l'ophtalmologie, et son principal actionnaire Wise Equity, annoncent la finalisation de l'acquisition de Pharmathen's ophthalmology business. L'acquisition ajoute à NTC un portefeuille consolidé et mondial de traitements du glaucome, fabriqués dans diverses installations
More news about: NTC Srl
Dec 09, 2025, 19:26 ET Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 1 clinical trial of IBI3011, an anti-human
More news about: Innovent Biologics
Dec 09, 2025, 15:07 ET Schwarzman Animal Medical Center Completes a Four-Year, 83,000 Square-Foot, and $125 Million Transformation
expansion and renovation. The just completed final phase of construction includes a new Emergency Room and new facilities for Cardiology, Radiology, Ophthalmology, Neurology, and Internal Medical services. This marks the first renovation of this scale in 60 years.
More news about: Schwarzman Animal Medical Center
Dec 09, 2025, 09:10 ET Physician Growth Partners Strengthens Eye Care M&A Track Record, Advises Spokane Eye Clinic In Partnership With PRISM Vision Group
Spokane Eye Clinic ("SEC"), a premier independent ophthalmology group based in Spokane, WA, on its strategic partnership with PRISM Vision Group.
More news about: Physician Growth Partners
Dec 09, 2025, 08:52 ET Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials
More news about: Zydus Lifesciences
Dec 09, 2025, 08:17 ET AMSURG Enters Central Pennsylvania Market With New Acquisition
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. Guided by its core values — Care Deeply, Champion Excellence, Cultivate Integrity and Celebrate Teamwork — AMSURG is committed
More news about: AMSURG Corporation
Dec 08, 2025, 08:00 ET EyeYon Medical Ltd. Receives FDA IDE Approval to Initiate U.S. Clinical Study of EndoArt®, the First Artificial Endothelial Layer for Corneal Edema
device company dedicated to developing innovative solutions for corneal diseases. EyeYon Medical is addressing one of the biggest unmet needs in ophthalmology - the lack of effective, accessible solutions for corneal blindness with only one cornea available for 70 patients in need. In the United States,
More news about: EyeYon Medical
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled
More news about: Innovent Biologics
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List
More news about: Innovent Biologics
Dec 05, 2025, 14:37 ET Salt Lake City Oculoplastic Surgeon Dr. Kian Eftekhari to Present Innovative Ptosis Technique at International ABAM Conference
completed his ophthalmology residency at the University of Pennsylvania's Scheie Eye Institute and pursued an additional two years of subspecialty fellowship training in oculoplastic and facial surgery in Salt Lake City.Dr. Eftekhari is board-certified by the American Board of Ophthalmology and is an
More news about: Eyelid Center of Utah
Dec 05, 2025, 08:00 ET Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Dec 04, 2025, 04:16 ET Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials
More news about: MS Pharma
Dec 04, 2025, 04:15 ET Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials
More news about: MS Pharma